Disease | hepatorenal syndrome |
Phenotype | C0023890|liver cirrhosis |
Sentences | 8 |
PubMedID- 21484118 | Cystatin c: a predictor of hepatorenal syndrome in patients with liver cirrhosis. |
PubMedID- 25983746 | Treatment of hepatorenal syndrome (hrs) in patients with liver cirrhosis is still challenging and characterized by a very high mortality. |
PubMedID- 22094211 | hepatorenal syndrome occurs in patients with advanced liver cirrhosis and is associated with functional renal impairment and poor prognosis. |
PubMedID- 21757984 | In addition, renal dysfunction usually progresses to hepatorenal syndrome (hrs) with progression of liver cirrhosis and portal hypertension.2 patients with cirrhosis who develop hrs have very high mortality, and even with terlipressin and albumin only 40% respond and survive for 1 month after treatment.3 therefore, because renal dysfunction is directly linked to the mortality rate of cirrhotic patients, a precise assessment of renal function is required to estimate the prognosis and determine the correct therapeutic intervention and response. |
PubMedID- 22924265 | Diagnostical significance of dimethylarginine in the development of hepatorenal syndrome in patients with alcoholic liver cirrhosis. |
PubMedID- 20124895 | Purpose of review: the development of hepatorenal syndrome in liver cirrhosis leads to an increased morbidity and mortality in patients with cirrhosis. |
PubMedID- 23788898 | Secondary to hbv or hcv) accompanied by intensive regenerative processes,patients with adenocarcinoma metastases into the liver,liver cirrhosis complicated by hepatorenal syndrome,non-alcoholic fatty liver disease,renal failure. |
PubMedID- 22055590 | Serum cystatin c in advanced liver cirrhosis and different stages of the hepatorenal syndrome. |
Page: 1